Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Porsche vz. Aktie 121873030 / DE000PAG9113

06.11.2025 09:00:03

EQS-News: Porsche Opens First Integrated R&D Hub Outside Germany in Shanghai

EQS-News: Dr. Ing. h.c. F. Porsche AG / Key word(s): Miscellaneous
Porsche Opens First Integrated R&D Hub Outside Germany in Shanghai

06.11.2025 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


“In China, for China”: Bridging German Engineering with China’s Digital Ecosystem

Shanghai, 6 November 2025 – Porsche has officially opened its first integrated overseas R&D center in Shanghai’s Hongqiao CBD, marking a major milestone in its “In China, for China” strategy. The 10,000-square-meter facility, operational from 5 November 2025, is designed to accelerate local innovation by merging Porsche’s engineering excellence with China’s fast-paced digital ecosystem.

The opening ceremony was attended by Porsche AG board members, Shanghai government officials, and strategic partners, highlighting the center’s significance in Porsche’s global innovation roadmap.

“China is leading the way in future mobility, combining electrification, digitalization, and new luxury concepts,” said Dr. Oliver Blume, Chairman of the Executive Board of Porsche AG, at the opening ceremony. “Solving the challenges of this transformation isn’t possible from afar – it has to happen here. The China R&D is a strategic pillar that connects German engineering with China's digital future. This center will help us move faster, learn more, and strengthen Porsche R&D globally.”

A Strategic Leap in Local Innovation

The new R&D facility consolidates Porsche’s existing operations – including the Technical Division, Porsche Engineering China, and Porsche Digital China – into a single, comprehensive hub. With over 300 engineers already on site, the center integrates R&D, procurement, and quality functions to operate with enhanced autonomy and agility.

“Today marks a defining moment in our commitment to China," said Alexander Pollich, President and CEO of Porsche China. "This center is our promise to deliver intelligent solutions that deeply connect to the digital life and specific needs of our Chinese customers, while unmistakably being Porsche in every drive, as well as maintaining Porsche's engineering quality and reliability standards.”

Accelerating Development with “China Speed”

The Shanghai R&D hub is already delivering results. Its first major achievement is a next-generation, China-exclusive infotainment system, set to launch across several Porsche model lines starting mid-2026.

“The China R&D allows us to tap directly into the country's fast-moving innovation ecosystem. This has enabled a significant acceleration of our development pace, cutting cycle times from years to months. As a result, we can respond to the evolving needs of Chinese customers with greater speed and in a more targeted manner,” said Sajjad Khan, member of the Executive Board Car-IT.

“It brings Porsche's iconic design philosophy into the digital world with bold, clarity and precision,” said Li Nan, head of China R&D and vice president of Technical Division of Porsche China. “Featuring an AI-powered voice assistant based on large language models, immersive 3D vehicle controls, and deep integration with China's digital ecosystem, this system represents how we’re creating intelligent experiences that resonate locally while staying true to our global brand DNA.”

A Decade of Local R&D Evolution

Porsche’s journey in China began in 2014 with the establishment of Porsche Engineering’s Shanghai office. This was followed by the founding of Porsche Digital China in 2021 and the launch of a local R&D satellite in 2022. The new center builds on this foundation to become both an extension of Porsche’s core R&D in Weissach and a standalone innovation powerhouse.

“Our China R&D is founded on many years of innovation in this country. It will complement our R&D Center in Weissach and act as an additional innovation hub, leveraging China’s fast-evolving technology landscape,” said Dr. Michael Steiner, Member of the Executive Board for R&D. “By combining our engineering excellence with China’s digital strengths, we aim to create something truly unique.”

 



06.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Dr. Ing. h.c. F. Porsche AG
Porscheplatz 1
70435 Stuttgart
Germany
Phone: +497119110
E-mail: info@porsche.de
Internet: https://www.porsche.com/international/
ISIN: DE000PAG9113
WKN: PAG911
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard)
EQS News ID: 2224824

 
End of News EQS News Service

2224824  06.11.2025 CET/CEST

Analysen zu Porsche AG Vz (Dr. Ing. h.c. F. Porsche Aktiengesellschaft)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
12:20 Porsche vz. Buy Deutsche Bank AG
28.10.25 Porsche vz. Market-Perform Bernstein Research
27.10.25 Porsche vz. Sector Perform RBC Capital Markets
27.10.25 Porsche vz. Equal Weight Barclays Capital
27.10.25 Porsche vz. Buy Deutsche Bank AG
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’813.11 19.94 S2S3YU
Short 13’084.51 13.89 U5BSSU
Short 13’569.35 8.96 UJOBSU
SMI-Kurs: 12’298.86 06.11.2025 17:31:06
Long 11’804.58 19.62 SG1BPU
Long 11’547.40 13.89 BO0SVU
Long 11’054.12 8.96 S9VBWU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com